InMed Pharmaceuticals Inc
MWG
Company Profile
Business description
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Contact
885 West Georgia Street
Suite 1445
VancouverBCV6C 3E8
CANT: +1 604 669-7207
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2027
Employees
13
Stocks News & Analysis
stocks
Nvidia earns upgrade as AI buildouts accelerate
Demand for AI infrastructure shows no signs of slowing.
stocks
Weekly earnings wrap: FMG, WDS, COL and more
A closer look at the final major results from August reporting season.
stocks
Chart of the Week: Are US mega-cap stocks undervalued?
Opportunities emerge across US equities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,243.20 | 84.80 | -0.91% |
| CAC 40 | 8,315.81 | 146.58 | -1.73% |
| DAX 40 | 26,357.55 | 71.59 | 0.27% |
| Dow JONES (US) | 53,702.89 | 239.01 | 0.45% |
| FTSE 100 | 10,797.53 | 80.59 | -0.74% |
| HKSE | 25,565.74 | 87.23 | -0.34% |
| NASDAQ | 26,461.58 | 331.38 | 1.27% |
| Nikkei 225 | 66,131.98 | 130.18 | -0.20% |
| NZX 50 Index | 13,880.05 | 133.16 | -0.95% |
| S&P 500 | 7,725.46 | 49.76 | 0.65% |
| S&P/ASX 200 | 9,038.20 | 78.20 | -0.86% |
| SSE Composite Index | 3,956.57 | 44.05 | 1.13% |